Ozempic’s near-to medium-term risks are overblown, notes CFRA Research’s Arun Sundaram. He discusses the Ozempic effect of 2023. He talks about how while longer-term risks could be more justified, food and beverage manufacturers have time to innovate. He suggests that by 2030, we see total food and beverage consumption down by a modest 1% to 2% due to the rise of AOMs, and categories that are at most risk are those that are high in fat, sugar, sodium, or carbs. He then goes over CFRA’s top packaged food picks for 2024. CFRA has a strong buy rating on Mondelez (MDLZ), Kraft Heinz (KHC), Coca-Cola (KO), and PepsiCo (PEP). Tune in to find out more about the stock market today.